Nature Reviews Drug Discovery

Papers
(The H4-Index of Nature Reviews Drug Discovery is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The importance of persistence in cancer drug development2147
A new path to targeted protein degradation?1266
A specific biomarker for insoluble tau834
Targeting tumour-associated bacteria714
The improving benefit–risk balance of phase I cancer trials664
Neutralizing Zika virus553
Vaccine exposes tumours to immune cell attack534
Pfizer buys Biohaven’s migraine drugs for $11.6 billion532
Promoting tissue repair after heart attack488
mRNA-encoded monoclonal antibody fights CHIKV472
AI serves up target and inhibitor for lung fibrosis464
Hypoimmune iPSCs escape immune detection435
Glucose-sensitive insulin protects against hypoglycaemia424
Tumour cells get a dendritic cell makeover402
Degrading cell-free DNA to prevent recurrent stroke393
FDA new drug approvals in Q1 2023392
Apolipoprotein L2 inhibitor mitigates fibrosis388
Lipid nanoparticle ferries therapeutic mRNA to the placenta366
FDA approves second TTR stabilizer for cardiac amyloidosis332
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval324
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer300
Top companies and drugs by sales in 2021292
Targeting drug-resistant glioblastoma288
Evolution of innovative drug R&D in China270
FDA approves a c-MET-targeted ADC for lung cancer268
2022 FDA approvals267
Anti-tau antibody stumbles in phase II Alzheimer trial266
mRNA vaccines for infectious diseases — advances, challenges and opportunities265
Chemical engineering of CRISPR–Cas systems for therapeutic application257
Small-molecule discovery through DNA-encoded libraries249
Targeting the Hippo pathway in cancer241
New antibiotic for urinary tract infections nabs FDA approval239
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets228
Increasing the potency of T cell therapies223
Pushing both sides of the drug pricing aisle218
Reflections on 10 years of the FDA’s breakthrough therapy designation211
Blocking breast cancer metastasis206
Rewired proteostasis in KRAS inhibitor resistance190
Small molecule improves muscle function in myasthenia gravis183
R&D re-balancing act182
FDA approves anti-CD3 antibody to delay type 1 diabetes onset182
Host-directed antiviral blocks SARS-CoV-2 entry172
The significance of blockbusters in the pharmaceutical industry167
Amylin takes another shot at the obesity prize165
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases161
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation160
Inhibiting ASGR1 boosts cholesterol removal159
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders158
FDA new drug approvals in Q2 2023155
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines151
TCR-engineered T cells get personal147
FDA approves second BCMA-targeted CAR-T cell therapy144
Mimicking the health benefits of exercise134
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer134
Base editors hit the clinic130
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics130
Screening ultra-large virtual libraries128
The antibody–drug conjugate landscape128
Combating antimicrobial resistance in malaria, HIV and tuberculosis120
Pan-coronavirus vaccine pipeline takes form118
A call to action for translational sciences in COVID-19 and future pandemics115
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap107
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape104
The emerging role of mass spectrometry-based proteomics in drug discovery103
Antibody–drug conjugates come of age in oncology101
Phenotypic drug discovery: recent successes, lessons learned and new directions99
Gut metabolite mediates nerve repair98
Reducing IL-2 toxicity96
A novel single-agent antibiotic94
Agonist antibody lowers blood pressure94
Immunology on the brain92
Multi-TACs target solid tumours91
The malignant melanoma market90
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis87
Neglected tropical diseases go global84
Monkeypox mRNA vaccine protects mice and macaques81
The European Innovation Network as a hub for medicines innovation in Europe81
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline80
Anti-IL-11 antibody shows anti-ageing properties80
0.082628011703491